Canris Pharma India Private Limited - Due diligence report

A 360° intelligence report on Canris Pharma India Private Limited: trust score, financial health, credit view, compliance, directors, growth…

2012-03-28 Bangalore, Karnataka Strike Off Unlisted Active Compliant
Share
View plans
CP Canris Pharma India Private Limited

Canris Pharma India Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
56/100
Trust Score
Moderate

Canris Pharma India Private Limited is assessed as Moderate with a Trust Score of 56/100. Canris Pharma India Private Limited is a private limited indian non-government company incorporated in 2012, operating in the Pharma sector. Processed financial statements are not yet available for trend analysis. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.

Report generated on 13 Jun 2026 from the latest processed filings. Canris Pharma India Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
56/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
30/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
80/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreNo Data
N/A
Needs at least two filed years to measure growth.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 1 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 80/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Elevated gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 30/100 Caution Indicated
  • Company status is "Strike Off" - not Active.
  • Last balance sheet is for Mar 2020 - filings overdue.
05

Director Intelligence

Stability score: 55/100
NameDIN / PANDesignationAppointedTenureDIN status
CHIKKAPURA SHANTHAVEERAPPA NAGARAJA 01234567 Director 01/04/2018 6 yrs Approved
MOHAN KUMAR RAJANNA 01234567 Director 01/04/2018 6 yrs Approved
MAHANTESH RACHAYYA CHARANTIMATH 01234567 Director 01/04/2018 6 yrs Approved
DEVARAHALLY KARIBASAVASHASTRY JAMUNA 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • DEVARAHALLY KARIBASAVASHASTRY JAMUNA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2017 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth N/A · Distress 55
Growth signals & trust indicators
Operating for 14+ years.
Distress signals & risk flags
Statutory filings appear overdue.
Adverse company status: Strike Off.
Compliance score is weak (30/100).
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence45/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment64/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view38/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 9 events
31 Dec 2020
Last AGM held
Annual general meeting
31 Mar 2020
Latest balance sheet
Filed with ROC
02 Aug 2018
Director ceased
VENKATESH PRASANNA KUMAR
05 Dec 2016
Director appointed
MOHAN KUMAR RAJANNA (Director)
Director appointed
MAHANTESH RACHAYYA CHARANTIMATH (Director)
Director ceased
DEVARAHALLY KARIBASAVASHASTRY JAMUNA
28 Mar 2012
Incorporated
Registered with Roc Bangalore
Director appointed
CHIKKAPURA SHANTHAVEERAPPA NAGARAJA (Director)
Director appointed
DEVARAHALLY KARIBASAVASHASTRY JAMUNA (Director)
10

Key Observations

Auto-generated from the data above
4 active director(s) / partner(s); review board churn before relying on management continuity.
Promoters hold a dominant controlling stake as per the FY 2017 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Lepidus Pharma India Private Limited U74900TG2015PTC097925 Hyderabad, Telangana, India
Odex Chemicals Pvt Ltd U24231GJ1985PTC007872 Pardi, Gujarat, India
Alcove Vanijya Private Limited U51909WB2011PTC160588 Kolkata, West Bengal, India
Astran Pharmaceuticals Private Limited U24233TN2012PTC086070 Thanjavur, Tamil Nadu, India
Highend Mercantile Private Limited U74999MH2007PTC168794 Mumbai, Maharashtra, India
Prina Era Energy Resources Private Limited U74900CH2011PTC033154 Chandigarh, Chandigarh, India
Croyance Agro India Private Limited U01403MH2015PTC264220 Nashik, Maharashtra, India
Ramdarbar Sales Private Limited U51909WB2011PTC160489 Kolkata, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Canris Pharma India Private Limited before audits and certifications: compliance score 30/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Canris Pharma India Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 80/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score n/a, margin trends, ownership structure and peer set for Canris Pharma India Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 56/100, distress signals and MSME payment-delay disclosures - know whether Canris Pharma India Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Canris Pharma India Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Canris Pharma India Private Limited an active company?

Canris Pharma India Private Limited has MCA status “Strike Off” with a compliance score of 30/100 (Caution Indicated).

Is Canris Pharma India Private Limited financially healthy?

Canris Pharma India Private Limited has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.

Should I do business with Canris Pharma India Private Limited?

Its overall Trust Score is 56/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Canris Pharma India Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Canris Pharma India Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Canris Pharma India Private Limited up to date with its ROC filings?

Last balance sheet is for Mar 2020 - filings overdue. Overall compliance score: 30/100 (Caution Indicated).

Is it risky to lend to Canris Pharma India Private Limited?

Its Credit Risk Score is 80/100 (Low Risk). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.